These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25274791)

  • 1. A review of osteocyte function and the emerging importance of sclerostin.
    Compton JT; Lee FY
    J Bone Joint Surg Am; 2014 Oct; 96(19):1659-68. PubMed ID: 25274791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
    Sapir-Koren R; Livshits G
    Osteoporos Int; 2014 Dec; 25(12):2685-700. PubMed ID: 25030653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone and Nutrition. Sclerostin and bone metabolism].
    Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
    Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody.
    Morrell AE; Robinson ST; Ke HZ; Holdsworth G; Guo XE
    Bone; 2021 Aug; 149():115967. PubMed ID: 33892178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.
    Yan Y; Wang L; Ge L; Pathak JL
    Curr Osteoporos Rep; 2020 Feb; 18(1):67-80. PubMed ID: 31953640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
    Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
    FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
    Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
    Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin and Bone Aging: A Mini-Review.
    Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
    Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.
    Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J
    Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
    Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
    Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteocytes.
    Rupp M; Merboth F; Daghma DE; Biehl C; El Khassawna T; Heiß C
    Z Orthop Unfall; 2019 Apr; 157(2):154-163. PubMed ID: 30366349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size.
    Kogawa M; Khalid KA; Wijenayaka AR; Ormsby RT; Evdokiou A; Anderson PH; Findlay DM; Atkins GJ
    Am J Physiol Cell Physiol; 2018 Jan; 314(1):C53-C61. PubMed ID: 28978523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.
    Pathak JL; Bravenboer N; Klein-Nulend J
    Front Endocrinol (Lausanne); 2020; 11():405. PubMed ID: 32733380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin and skeletal health.
    Sharifi M; Ereifej L; Lewiecki EM
    Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.
    Power J; Poole KE; van Bezooijen R; Doube M; Caballero-Alías AM; Lowik C; Papapoulos S; Reeve J; Loveridge N
    J Bone Miner Res; 2010 Aug; 25(8):1867-76. PubMed ID: 20200987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of osteocyte-mediated regulation of bone remodelling in inflammatory bone disease.
    Intemann J; De Gorter DJJ; Naylor AJ; Dankbar B; Wehmeyer C
    Swiss Med Wkly; 2020 Jan; 150():w20187. PubMed ID: 32031236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
    Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
    EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anabolic therapies.
    Lane NE; Silverman SL
    Curr Osteoporos Rep; 2010 Mar; 8(1):23-7. PubMed ID: 20425087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.